Survival Benefit of Recombinant Human Erythropoietin Administration prior to Onset of End-Stage Renal Disease: Variations across Surrogates for Quality of Care and Time

Publisher： Karger

E-ISSN： 1660-2110|101|2|c79-c86

ISSN： 1660-2110

Source： Nephron Clin Pract, Vol.101, Iss.2, 2005-06, pp. : c79-c86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sociodemographic and Geographic Predictors of Quality of Care in United States Patients With End‐Stage Renal Disease Due to Lupus Nephritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 3, 2015-03 ,pp. : 761-772

John Wiley & Sons Inc

Access to resources Recommend Favorite

Small Distal Muscles and Balance Predict Survival in End-Stage Renal Disease

By  

Nephron Clin Pract, Vol. 126, Iss. 3, 2014-04 ,pp. : 116-123

Karger

Access to resources Recommend Favorite

Oxidative Stress in Patients with End-Stage Renal Disease prior to the Start of Renal Replacement Therapy

By  

Nephron Clin Pract, Vol. 98, Iss. 1, 2004-11 ,pp. : c3-c7

Karger

Access to resources Recommend Favorite

Improved Immunogenicity of a Novel Third-Generation Recombinant Hepatitis B Vaccine in Patients with End-Stage Renal Disease

By  

Nephron Clin Pract, Vol. 97, Iss. 2, 2004-11 ,pp. : c67-c72

Karger

Access to resources Recommend Favorite

QT–interval parameters in end–stage renal disease

By Cardoso C.   Salles G.  

Clinical Autonomic Research, Vol. 14, Iss. 4, 2004-08 ,pp. : 214-216

Springer Publishing Company

Access to resources Recommend Favorite